Key clinical validation progress and expanded patient reach were achieved, with a positive Q2 net result of 2,645 TSEK and successful capital raises. Results from the SPLENDOUR lung cancer study are expected in Q3 2025, supporting ongoing partnering and licensing efforts.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.